Please login to the form below

Not currently logged in

Former Sanofi SVP to chair Idera

James Geraghty joins the firm with 20 years biotech experience from Genzyme

James Geraghty, IderaIdera Pharmaceuticals has named James Geraghty as the company's new chairman.

Idera specialises in developing toll-like receptors (TLRs) for autoimmune and inflammatory conditions and will benefit from Geraghty's extensive career in the life sciences industry, which includes 20 years ion senior roles at leading biotech Genzyme.

He was later appointed senior VP, North America strategy at Sanofi after the company took over Genzyme in 2011, before leaving earlier this year to become entrepreneur-in-residence at venture capital firm Third Rock Ventures.

“I believe that the addition of Jim and his extensive experience comes at an ideal moment, and we look forward to his guidance and contributions as we advance our programmes toward later stage development,” said Dr Sudhir Agrawal, CEO of Idera.

These programmes involve the company's TLR antagonist drug candidates, which Idera says have shown proof-of-concept in clinical trials and are set for further studies in psoriasis and other conditions.

19th July 2013

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
Adelphi Research UK

Adelphi Research UK is a healthcare insight partner. We uniquely blend robust market research with a consultancy approach, to guide...

Latest intelligence

Waking the sleeping giant
The lights are coming on for healthcare delivery in Africa...
How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...